为您找到相关结果约17个

你是不是要搜索 期刊Eprenetapopt 点击跳转

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions

Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced

Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A

Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches

Transplant for TP53-mutated MDS and AML: because we can or because we should?

Current Therapy of the Patients with MDS: Walking towards Personalized Therapy

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia

为您找到相关结果约17个

共17条页码: 1/2页15条/页